Who Supplies Carboplatin to India from UNITED STATES

To import finished pharmaceutical formulations containing Carboplatin into India, the importing company must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41, along with necessary documents such as the Free Sale Certificate, Good Manufacturing Practice (GMP) Certificate, and Certificate of Pharmaceutical Product (CoPP). The registration certificate is valid for three years from the date of issue. The timeline for obtaining the Import Registration Certificate is approximately nine months from the date of application.

Imported pharmaceutical formulations containing Carboplatin must undergo quality testing at CDSCO-approved laboratories. The importer is required to submit samples from three consecutive batches for testing, providing adequate samples for reanalysis purposes. The testing includes analysis methods, Certificates of Analysis (CoA) from the exporting country's laboratory, impurity standards, marker compounds, and reference standards. The importer is responsible for the testing fees, which are paid directly to the testing laboratory.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing Carboplatin, require an Import Registration Certificate and an Import License. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy also stipulates that drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution.

India imports finished Carboplatin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for manufacturing Carboplatin formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Carboplatin formulations in India is substantial, with a total export market of $70.9 million across 273 exporters to 138 countries.

Imports of finished pharmaceutical formulations containing Carboplatin under HS Code 30049047 are subject to a Basic Customs Duty (BCD) of 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable, calculated on the assessable value plus applicable customs duties. A Social Welfare Surcharge (SWS) of 10% on the BCD is levied. There are no preferential duty rates or exemptions available for imports from the United States.

India sources finished Carboplatin formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality products. The United States holds a competitive advantage in the production of these formulations, offering products that may not be manufactured domestically. Other suppliers include China and Germany; however, the United States's share in the Indian market is significant.

India imports finished Carboplatin formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality products that are not manufactured domestically. The United States's advanced pharmaceutical manufacturing capabilities and adherence to stringent quality standards make it a preferred source for these formulations.

Compared to other origins such as China and Germany, the United States offers superior quality, regulatory compliance, and reliability in the production of finished Carboplatin formulations. While other suppliers may offer lower prices, the United States's products are preferred for their quality and adherence to international standards.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, ensure robust quality assurance processes, and maintain contingency plans for shipping disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

1. 1Obtain Importer Exporter Code (IEC): Register with the Directorate General of Foreign Trade (DGFT).
2. 2Apply for CDSCO Import Registration Certificate: Submit Form 40/41 with required documents.
3. 3Obtain Import License: Apply for a Form 10 license from CDSCO.
4. 4Secure No Objection Certificate (NOC): If required, obtain NOC from relevant authorities.
5. 5Engage Customs Broker: Appoint a licensed customs house agent for clearance.
6. 6Seek Advance Ruling: Obtain advance ruling for HS Code 30049047 if necessary.